Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept Imaging in Rheumatoid Arthritis
NCT02683421Phase 1Completed
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Jul 2016
- Primary completion
- Dec 2016
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA) (4 arms), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Localization of Tc 99m Tilmanocept by Planar and SPECT/CT Imaging in Subjects With Active RA and Concordance With Swollen/Tender Joints. Started Jul 2016; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02683421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683421.